Harvoni (Ledipasvir/Sofosbuvir) Patent Expiration, LOE Window & CMS Spending

Harvoni (Ledipasvir/Sofosbuvir) by Gilead Sciences: FDA Orange Book core substance LOE 2034-07-30, 0 AB generics, $39.8M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorGilead Sciences
FDA Application & PathwayN205834 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE Date2034-07-30
Last Listed Patent or Exclusivity Date2034-07-30
Orange Book Patents (*PED Extensions)33 patents (16 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$39.8M
2024 Medicare Part D Spend$35.9M
2024 Medicaid Spend$3.9M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Gilead Sciences across sibling Meru public-data platforms.